Left ventricular hypertrophy (LVH) represents an independent risk factor for cardiovascular morbidity and mortality, and normalization of left ventricular mass has become a desirable goal of
antihypertensive treatment. In a randomized, double-blind study, the
angiotensin II (AT1-receptor) antagonist
valsartan (
Diovan ; 80-160 mg q.d.) was compared with the beta-blocker
atenolol (50-100 mg q.d.) over 8 months in previously untreated patients with
essential hypertension and LVH. Sixty-nine patients were randomized, of whom 58 were evaluated by echocardiography. After 8 months of treatment in the
atenolol group [n = 8 with additional
hydrochlorothiazide (
HCTZ)], initial blood pressure was reduced from 160/103 to 147/92 mm Hg (p < 0.0001). In the
valsartan group (n = 9 with
HCTZ), blood pressure decreased from 163/101 to 146/90 mm Hg (p < 0.0001). Left ventricular mass index decreased from 127 to 117 g/m2 in the
atenolol group and from 127 to 106 g/m2 in the
valsartan group. Long-term treatment with
valsartan resulted in a significant reduction of LVH in patients with
essential hypertension.